Batch BeaconUK recalls and safety alerts

Medicines defect noticeMHRA

Gabapentin Relonchem 50mg/ml Oral Solution defect notice over possible contamination

Contamination or sterilityLow riskClass 4

Relonchem Limited have informed the MHRA that particles have been observed inside some bottles of Gabapentin Relonchem Oral Solution, identified through a customer complaint.

Check your product

Only products that match these details are covered. Have your pack in front of you.

16 identifiers listed for this notice.

  • Gabapentin Relonchem 50mg/ml Oral Solution 150ML

    Batch codePrinted on the pack, often next to the date mark. It may start with L or LOT.
    • 09E1
    • 11E1
    • 12E1
    • 13E1
    • 14E1
    • 19F1
    • 21F1
    ExpiryOn the carton, blister or label.
    • 01/10/2026
    • 01/12/2026
    • 01/03/2027
    • 01/04/2027
    First distributedOn the product, its label or its packaging.
    • 12/11/2025
    • 02/01/2026
    • 20/01/2026
    • 08/04/2026
    • 12/05/2026

What to do now

Gabapentin Relonchem 50mg/ml Oral Solution has been recalled because the product may not be as clean or sterile as it should be.

  1. Keep taking your medicine unless a healthcare professional tells you otherwise.
  2. Check the batch number and expiry date on your pack against the list on this page.
  3. If it matches, your pharmacist can swap it or arrange an alternative.
  4. Report suspected side effects to the MHRA Yellow Card scheme.

Why it matters. Contamination matters most for injections, eye drops and products used on broken skin, where it could cause infection.

Symptoms and when to get help

Look out for

  • redness, swelling or pain where the product was used
  • a high temperature

Get help urgently

  • signs of a severe allergic reaction, such as swelling of the face or throat or difficulty breathing — call 999
  • if you feel unwell and are worried, speak to a pharmacist, your GP or NHS 111

This is general information based on NHS public guidance, not medical advice. In an emergency call 999. For urgent advice use NHS 111 (NHS 24 on 111 in Scotland) or, in Northern Ireland, your GP or out-of-hours service.

Replacements and prescriptions

The MHRA notice tells pharmacies and healthcare professionals what to do. Patients should keep taking their medicine and ask a pharmacist before stopping.

An affected pack bought over the counter can be returned to where you bought it.

From the official notice

Published by the Medicines and Healthcare products Regulatory Agency (EL(26)A/31). Quoted as issued.

Summary

Relonchem Limited have informed the MHRA that particles have been observed inside some bottles of Gabapentin Relonchem Oral Solution, identified through a customer complaint.

The risk

This Class 4 Medicines Defect Notification has been updated since its initial publication on 30 June 2026 to correct the expiry date for Gabapentin Relonchem 50 mg/ml Oral Solution, batch 21F1. Relonchem Limited has advised that the expiry date previously provided for batch 21F1 was incorrect. The correct expiry date is 01/04/2027. All other batch details remain unchanged. Please ensure that the actions set out in this notification are undertaken for this batch.

Advice for healthcare professionals

check the existing stock within your possession and identify if any of the Gabapentin Relonchem 50mg/ml Oral Solution batches listed above are impacted by this issue. The visual check should be done at the point of dispensing or administration. Please note that in addition to dispensaries, this may include clinics, wards and any other relevant locations

ensure that the bottles are checked prior to dispensing for any visible crystals and return the bottles through your usual process if crystals are identified. For ease of checking presence of crystals, the bottles may be gently rotated once or twice

the product should be stored according to the storage instructions (do not store above 25°C) and ideally the product should not be stored below 15°C

if Gabapentin 50 mg/mL Oral Solution is being used for administration via feeding tubes (NG/PEG), alternate formulations should be considered, as there is a potential for obstruction of feeding tubes. Clinical judgement may be required for individual cases. More advice can be sought from Relonchem Limited via the contact details in this notification

if there are any concerns raised by patients, they should be advised to contact a healthcare professional to obtain a new bottle but should not stop taking the medication unless directed by their physician

Healthcare professionals are advised to review the information contained within this notification and take this into account when dispensing this product.

Patients who have this medication at home should follow the storage instructions on the label. The product storage instruction state: Do not refrigerate or freeze. Do not store above 25°C.

Gabapentin 50 mg/mL Oral Solution should be stored at room temperature (below 25°C) and ideally above 15°C to prevent crystallization. If patients observe particles in the solution or there are any concerns, patients are advised to seek advice from a healthcare professional.

Never stop taking medicines such as gabapentin without medical advice. Suddenly stopping a medicine used for epilepsy, may cause your seizures to start again or happen more often or last longer than before. Suddenly stopping gabapentin when used for pain may impact your pain control.

Patients who have any additional concerns related to this information should contact their pharmacist in the first instance.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme .

Advice for patients

Patients who have this medication at home should follow the storage instructions on the label. The product storage instruction state: Do not refrigerate or freeze. Do not store above 25°C.

Gabapentin 50 mg/mL Oral Solution should be stored at room temperature (below 25°C) and ideally above 15°C to prevent crystallization. If patients observe particles in the solution or there are any concerns, patients are advised to seek advice from a healthcare professional.

Never stop taking medicines such as gabapentin without medical advice. Suddenly stopping a medicine used for epilepsy, may cause your seizures to start again or happen more often or last longer than before. Suddenly stopping gabapentin when used for pain may impact your pain control.

Patients who have any additional concerns related to this information should contact their pharmacist in the first instance.

Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme .

Open the MHRA notice

Questions

Why has Gabapentin Relonchem 50mg/ml Oral Solution been recalled?

Gabapentin Relonchem 50mg/ml Oral Solution has been recalled because the product may not be as clean or sterile as it should be. Contamination matters most for injections, eye drops and products used on broken skin, where it could cause infection.

How do I know if my medicine is affected?

Compare the batch code, expiry and date code on your pack with the details listed under “Check your product” on this page. Only items that match are covered by the notice.

What should I do now?

Keep taking your medicine unless a healthcare professional tells you otherwise. Check the batch number and expiry date on your pack against the list on this page.

Do I need a new prescription?

The MHRA notice tells pharmacies and healthcare professionals what to do. Patients should keep taking their medicine and ask a pharmacist before stopping. An affected pack bought over the counter can be returned to where you bought it.

Related notices